E-Mail
Some of the most commonly used drugs for treating hereditary breast and ovarian cancers may not work the way we thought they did, according to new University of Colorado Boulder research.
The paper, published February 2 in the journal
Nature Communications, sheds new light on how they do work and could open the door to new next-generation medications that work better, the authors said. Despite the success of these drugs which sell in the billions of dollars per year and treat many thousands of patients, there are many unknowns about their potency and efficacy that if better understood could lead to improvements, said senior author Karolin Luger, a professor in the Department of Biochemistry. Our paper provides a fuller picture.